Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04236921 in Crohn's Disease (ANDANTE)
NCT01287897Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2011
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial of pacibekitug in Crohn's disease (4 arms), sponsored by Pfizer. Primary endpoint: Crohn's Disease Activity Index-70 Response Rate at 12 weeks. Started Feb 2011; status: completed.
02
Drugs
pacibekitug
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01287897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01287897.